Anthony Killarney
Chief Executive Officer at Towercom Ltd.
Network origin in Anthony Killarney first degree
Entity | Entity type | Industry | |
---|---|---|---|
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland.
11
| Holding Company | Biotechnology | 11 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Anthony Killarney via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | Medical Specialties | Director/Board Member Director/Board Member | |
Cormorant Asset Management LLC/Private Equity/
Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
Loyola University of Chicago | College/University | Undergraduate Degree | |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
MOONLAKE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Blossom Biosciences Ltd.
Blossom Biosciences Ltd. BiotechnologyHealth Technology Blossom Biosciences Ltd. provides molecular and cell biology research services. The company is based in Hong Kong, Hong Kong. Andrew J. Phillips has been the CEO of the Chinese company since 2021. | Biotechnology | Chief Executive Officer | |
Aleksia Therapeutics, Inc. | Chief Executive Officer | ||
Blossom Biomedicines USA, Inc. | Director/Board Member | ||
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska. | Miscellaneous Commercial Services | Director/Board Member | |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Director/Board Member | |
Nexo Therapeutics, Inc.
Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022. | Pharmaceuticals: Major | Founder | |
The University of Colorado | College/University | Corporate Officer/Principal | |
ENLIVEN THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
NEON THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
AVANTOGEN ONCOLOGY, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Biotechnology | Corporate Officer/Principal | |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Novartis UK Ltd.
Novartis UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom. | Pharmaceuticals: Major | President | |
Novartis International Pharmaceutical Ltd.
Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PUMA BIOTECHNOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
Novartis Ireland Ltd. | President | ||
THERAPEUTICSMD, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
SPEXIS AG | Pharmaceuticals: Major | Director/Board Member | |
Arkuda Therapeutics, Inc.
Arkuda Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree | |
Stanford University | College/University | Doctorate Degree | |
Garuda Therapeutics, Inc.
Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | Biotechnology | Director/Board Member | |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
Kellstadt Graduate School of Business | College/University | Masters Business Admin | |
Yale University | College/University | Corporate Officer/Principal | |
KITE PHARMA INC | Biotechnology | Corporate Officer/Principal | |
FOGHORN THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO | |
GENOMIC HEALTH, INC. | Medical Specialties | Sales & Marketing | |
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
University of Western Ontario | College/University | Undergraduate Degree | |
University of Toronto | College/University | Doctorate Degree | |
Citigroup Alternative Investments LLC
Citigroup Alternative Investments LLC Investment ManagersFinance Citigroup Alternative Investments LLC (CAI) is a SEC-registered asset management firm headquartered in New York City. The firm was founded in 2002 and is a wholly-owned subsidiary of Citigroup Investments, Inc., which is owned by Citigroup, Inc. (NYSE: C). CAI provides advisory services to private investment companies, such as private equity funds and funds of one or more private equity and real estate funds. The investors in the funds advised by the firm are institutional investors, funds of funds, high-net worth individuals and employees, and former employees of Citigroup, Inc. | Investment Managers | Portfolio Manager-Equities | |
Lombard Odier Asset Management (USA) Corp.
Lombard Odier Asset Management (USA) Corp. Investment ManagersFinance Lombard Odier Asset Management (USA) Corp. (LOAM) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2000 and do-business-as Lombard Odier Investment Managers. The firm is a subsidiary of LO Holding SA and their ultimate parent is Switzerland-based Compagnie Lombard Odier SCmA. LOAM provides investment advisory services on a discretionary basis to private pooled investment vehicles (Funds) and investment advisory accounts. The investors in the Funds consist of endowments, foundations, insurance companies, high net-worth individuals, funds of funds, public and corporate pensions, and other sophisticated investors. | Investment Managers | Portfolio Manager-Equities | |
PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO | |
Cormorantasset Management LP | Corporate Officer/Principal | ||
PRIME MEDICINE, INC. | Biotechnology | Director of Finance/CFO |
Statistics
International
United States | 40 |
Switzerland | 4 |
United Kingdom | 4 |
Canada | 3 |
Hong Kong | 2 |
Sectoral
Health Technology | 28 |
Finance | 11 |
Consumer Services | 9 |
Commercial Services | 2 |
Operational
Director/Board Member | 33 |
Corporate Officer/Principal | 14 |
Chief Executive Officer | 10 |
President | 8 |
Undergraduate Degree | 5 |
Most connected contacts
Insiders | |
---|---|
Andrew Phillips | 23 |
Allan Reine | 14 |
Hugh O'Dowd | 11 |
Raymond Kelleher | 11 |
Eunan Maguire | 7 |
Christopher Nowers | 6 |
Mark Philip | 1 |
Michael O'Dwyer | 1 |
George Schlich | 1 |
Issac Manke | 1 |
Rohit Duggal | 1 |
- Stock Market
- Insiders
- Anthony Killarney
- Company connections